|
End-of-day quote
Shanghai S.E.
2026-01-19
|
5-day change
|
1st Jan Change
|
|
61.12 CNY
|
-1.32%
|
 |
-4.17%
|
+2.60%
|
|
25-09-02 |
TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
|
AQ
| |
25-08-20 |
Jiangsu Hengrui Medicine : Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results
|
PU
| |
24-08-01 |
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
|
AQ
| |
24-07-10 |
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type a FDA Meeting
|
AQ
| |
24-05-14 |
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
|
AQ
| |
24-02-08 |
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China
|
AQ
| |
23-12-05 |
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.
|
AQ
| |
23-11-22 |
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
|
AQ
| |
23-11-09 |
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
|
AQ
| |
23-09-27 |
Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)
|
AQ
| |
23-08-22 |
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China
|
AQ
| |
23-04-10 |
Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023
|
PU
| |
23-03-14 |
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type
|
AQ
| |
20-08-18 |
Thermo Fisher Scientific : Signs Companion Diagnostic Agreement with Hengrui Therapeutics Inc
|
AQ
| |
19-06-17 |
Jiangsu Hengrui Medicine : Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions
|
BU
| |
18-01-05 |
Jiangsu Hengrui Medicine : and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302
|
BU
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
